Business
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office ("USPTO") has granted the company U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders." The patent covers the propriety formulation used in IGC-AD1, the Company's lead drug candidate currently being evaluated in the Phase 2 CALMA (Clinically Advanced Lead Molecule for Agitation) trial for agitation in Alzheimer's disease.","length":772,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/3977fc2fe8531766b4fbabebb4440373"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ITiYTIuYLhtFNdt_8W1zjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/3977fc2fe8531766b4fbabebb4440373","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JU7waGVrIwnPJ1gPpSug8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/3977fc2fe8531766b4fbabebb4440373","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/81346975-11aa-40d8-94c3-625aacc63150/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The patent granted on November 11, 2025, covers a proprietary composition for treating Alzheimer's disease including amyloid plaque, tau tangles as well as symptoms associated with Alzheimer's, such as agitation, memory, cognition, anxiety, and sleep disturbances.","length":272,"tagName":"p"},{"type":"text","content":"Ram Mukunda, CEO of IGC Pharma, commented, "This patent further strengthens the robustness of our intellectual property portfolio as we move closer to commercialization of IGC-AD1. It reinforces our position in developing differentiated therapies that target both the behavioral and disease-modifying aspects of Alzheimer'...